Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
17 - Conception and pregnancy in myeloproliferative neoplasms
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 152 - 159Publisher: Cambridge University PressPrint publication year: 2016
References
Valera, MC,Parant, O, Vayssiere, C, et al. Essential thrombocythaemia and pregnancy. European Journal of Obstetrics and Gynaecology and Reproductive Biology 2011; 158: 141–7.CrossRefGoogle ScholarPubMed
Robinson, S, Bewley, S, Hunt, BJ, et al. The management and outcome of 18 pregnancies in women with polycythaemia vera. Hematologica 2005; 90: 1477–83.Google Scholar
Tulpule, S, Bewley, S, Robinson, SE, et al. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. British Journal of Haematology 2008; 142: 480–2.CrossRefGoogle ScholarPubMed
Barbui, T, Finazzi, G. Myeloproliferative disease in pregnancy and other management issues. Hematology 2006; 1: 246–52.Google Scholar
Melillo, L, Tieghi, A, Candoni, A, et al. Outcome of 122 pregnancies in essential thrombocythaemia patients: a report from the Italian registry. American Journal of Hematology 2009; 84: 636–40.CrossRefGoogle ScholarPubMed
Harrison, CN. Platelets and thrombosis in myeloproliferative diseases. Haematology 2005; 1: 409–15.Google Scholar
Gangat, N, Wolanskyj, AP, Schwager, S, et al. Estrogen based hormone therapy and thrombosis risk in women with essential thrombocythaemia. Cancer 2006; 106 (11): 2406–11.CrossRefGoogle Scholar
Harrison, C. Pregnancy and its management in Philadelphia negative myeloproliferative disease. British Journal of Haematology 2005; 129 (3): 293–306.CrossRefGoogle Scholar
Gangat, N, Wolanskyj, AP, Schwager, S, et al. Predictors of pregnancy outcome in essential thrombocythaemia: a single institution study of 63 pregnancies. European Journal of Haematology 2009; 82 (5): 350–3.CrossRefGoogle ScholarPubMed
Passamonti, F, Randi, ML, Rumi, E, et al. Increased risk of pregnancy complications in patients with essential thrombocythaemia carrying the JAK2 (617V>F) mutation. Blood 2007; 110 (2); 485–8.CrossRefGoogle ScholarPubMed
Passamonti, F, Rumi, E, Randi, ML. Aspirin in pregnant patients with essential thrombocythaemia: a retrospective analysis of 129 patients. Journal of Thrombosis and Haemostasis 2010; 8: 411–13.CrossRefGoogle ScholarPubMed
CLASP (Collaborative Low-dose Aspirin Study in Pregnancy). CLASP: a randomized trial of low dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343: 619–29.Google Scholar
Greer, IA, Nelson-Piercy, C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106 (2): 401–7.CrossRefGoogle ScholarPubMed
Greisshammer, M, Bergmann, L, Pearson, T. Fertility, pregnancy and the management of myeloproliferative disorders. Ballieres Clinical Haematology 1998; 11 (4): 859–74.Google Scholar
Liebelt, EL, Balk, SJ, Faber, W, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 2007; 80 4: 259–366.CrossRefGoogle Scholar
Sobas, MA, Perez Encinas, MM, Rabunal Martinez, MJ, et al. Anagrelide treatment in early pregnancy in a patient with JAK2 V617F positive essential thrombocythaemia: case report and literature review. Acta Haematologica 2009; 122 (4): 221–2.CrossRefGoogle Scholar
Cnossen, JS, Morris, RK, Riet, GT, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. Canadian Medical Association Journal 2008; 178(6):701–11.CrossRefGoogle ScholarPubMed
Llurba, E, Carreras, E, Gratacos, E, et al. Maternal history and uterine artery Doppler in the assessment of risk for development of early- and late-onset preeclampsia and intrauterine growth restriction. Obstetrics and Gynecology International 2009; 2009: 275613.CrossRefGoogle ScholarPubMed